LANCE Trial (Ovarian Cancer)

Purpose of this Study

We are doing this study to compare 2 different surgeries for epithelial ovarian cancer. We want to know if an investigational surgical procedure called minimally invasive surgery can offer better results than the standard surgery, which is called laparotomy. We hope to find out if one procedure or the other is preferable when it comes to preventing cancer from returning and giving patients a better quality of life after their surgery.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with stage IIIC or IV invasive epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian-tube carcinoma, or have pathology that is consistent with high-grade mullerian carcinoma
  • Have completed 3 or 4 cycles of platinum-based chemotherapy or an investigational neoadjuvant regimen
  • Are considered by their treating physician to be a suitable candidate for surgery
For more information about this study, please contact the study team at sarah.linhart@duke.edu.

Age Range

18-110

Sex/Genders

Female (cisgender)
Looking for Healthy Participants
Yes

What is Involved?

Description

If you choose to join this study, you will get a random assignment (like a coin flip) to one of 2 groups:
  • Group A: If you are in this group, you will have minimally invasive surgery.
  • Group B: If you are in this group, you will have a laparotomy.
Your participation in this study is expected to last 5 years. We will follow you through your pre-surgery chemo, surgery, and after surgery chemo. You will also fill out some questionnaires at the beginning of the study.

Locations

Duke University Hospital
Duke Raleigh Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE)

Principal Investigator

Jennifer
McNally

Protocol Number

PRO00106514

NCT ID

NCT04575935

Phase

III

Enrollment Status

Open to Enrollment